false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Onconep ...
Can We Predict and Prevent AKI Caused by Cytotoxic ...
Can We Predict and Prevent AKI Caused by Cytotoxic Cancer Therapies? Risk Scores, Nephroprotective Strategies, and Rescue Treatments
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Gabrielle Coté discussed predicting and preventing acute kidney injury (AKI) from cisplatin and high-dose methotrexate.<br /><br />Cisplatin AKI is common, dose-related, and more likely with chronic kidney disease, older age, comorbidities, dehydration, and nephrotoxic medications. A validated risk score can help identify higher-risk patients and guide closer monitoring—not automatically exclude them from treatment. Prevention includes IV hydration, stopping avoidable nephrotoxic drugs, avoiding hypotension, and considering IV magnesium. Mannitol is not routinely recommended; split dosing may be appropriate in selected cancers.<br /><br />Methotrexate can cause crystal-related tubular injury, especially with impaired clearance, dehydration, acidic urine, or drug interactions. Prevention relies on adequate hydration, urine pH above 7, close monitoring, and avoiding interacting medications. Leucovorin limits systemic toxicity, while glucarpidase rapidly provides a nonrenal route for methotrexate elimination and is preferred over dialysis for toxic levels with AKI. Prolonged bicarbonate infusion can cause harm and should be reassessed.
Asset Caption
Gabrielle Côté, MD, MSc
Meta Tag
Speaker
Gabrielle Côté
Keywords
acute kidney injury
cisplatin nephrotoxicity
high-dose methotrexate
risk prediction
hydration prevention
glucarpidase
×
Please select your language
1
English